Clinical Trial Update: Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of Flotetuzumab in pediatric patients with recurrent or refractory acute myeloid leukemia; results were posted in December 2023 and the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Flotetuzumab (flotetuzumab)

Snippet

Sponsor: Children's Oncology Group | Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-12-11